Cytomx analysts
WebCytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated … WebApr 14, 2024 · The consensus estimate for Apple’s current full-year earnings is $6.05 per share. KeyCorp also issued estimates for Apple’s Q3 2024 earnings at $1.11 EPS, Q4 2024 earnings at $1.48 EPS, FY2024 ...
Cytomx analysts
Did you know?
WebApr 14, 2024 · Analysts at StockNews.com initiated coverage on shares of DAVIDsTEA ( NASDAQ:DTEA – Get Rating) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating...
WebDXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security … WebMar 2, 2024 · InvestorsObserveris giving CytomX Therapeutics Inc (CTMX) an Analyst Rating Rank of 15, meaning CTMX is ranked higher by analysts than 15% of stocks. The average price target for CTMX is $3.564 and analyst’s rate the stock as a Buy. Wall Street analysts are rating CTMX a Buy today.
WebThe latest price target for . CytomX Therapeutics (NASDAQ: CTMX) was reported by Mizuho on March 28, 2024.The analyst firm set a price target for $2.00 expecting CTMX to rise to within 12 months ... WebNov 7, 2024 · Taking into account the latest results, the eight analysts covering CytomX Therapeutics provided consensus estimates of US$71.5m revenue in 2024, which would reflect a chunky 16% decline on its...
WebApr 9, 2024 · 8 Analysts CTMX Stock Overview CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. About the company Risk Analysis Negative shareholders equity Currently unprofitable and not forecast to become profitable over the next 3 years See All Risk Checks My Notes
WebWhat are analysts forecasts for CytomX stock? The 16 analysts offering price forecasts for CytomX have a median target of 6.42, with a high estimate of 16.00 and a low estimate … daily food intake guideWebApr 6, 2024 · Find the latest CytomX Therapeutics, Inc. (CTMX) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. … daily food intake log sheetWebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX– Get Rating) has received an average rating of “Hold” from the twelve analysts that are covering the firm, Marketbeatreports. One equities research... daily food for thoughtWebMar 30, 2024 · CytomX Therapeutics Stock Performance NASDAQ:CTMX opened at $1.54 on Thursday. The firm's fifty day simple moving average is $2.25 and its 200 day simple moving average is $1.84. CytomX Therapeutics has a twelve month low of $1.17 and a twelve month high of $3.02. Institutional Investors Weigh In On CytomX Therapeutics biohazard sign picsWebApr 5, 2024 · CytomX Therapeutics - CTMX News Today $1.80 -0.04 (-2.17%) (As of 03/21/2024 12:00 AM ET) Compare Today's Range $1.77 $1.87 50-Day Range $1.84 $2.86 52-Week Range $1.17 $3.12 Volume 946,693 shs Average Volume 2.86 million shs Market Capitalization $118.94 million P/E Ratio N/A Dividend Yield N/A Price Target $3.46 … daily food intake calorie calculatorWebMar 29, 2024 · So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. Check out our latest analysis for CytomX Therapeutics . NasdaqGS:CTMX Earnings and Revenue Growth March 29th 2024 biohazard specimen bags 6x9WebCytomX Therapeutics, Inc. Analyst Report: AbbVie Inc AbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. … biohazard spill clean up powder